Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC).

ESMO real world data and digital oncology·2026
Same author

Assessment of quality of life and wellbeing in mouse preclinical research - A scoping review.

Neuroscience applied·2025
Same author

Epigenetic inheritance of diet-induced and sperm-borne mitochondrial RNAs.

Nature·2024
Same author

Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer.

British journal of cancer·2023
Same author

[Technical modifications and outcome of the robot-assisted minimally-invasive esophagectomy (RAMIE)].

Chirurgie (Heidelberg, Germany)·2023
Same author

[Reconstruction and functional results after gastric resection].

Chirurgie (Heidelberg, Germany)·2022
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Improved immunotoxins with novel functional elements.

C Hetzel1, C Bachran, M K Tur

  • 1Fraunhofer IME, Department of Pharmaceutical Product Development, Forckenbeckstr. 6, 52074 AACHEN, Germany.

Current Pharmaceutical Design
|August 20, 2009
PubMed
Summary
This summary is machine-generated.

Immunotoxins (ITs) are protein-based cancer therapies. Researchers are developing strategies, including peptide sequence incorporation, to overcome challenges and enhance IT efficacy for improved cancer treatment.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Immunotoxins (ITs) are engineered proteins combining antibody-derived targeting with cytotoxic payloads for cancer cell elimination.
  • Clinical trials show promise for ITs, but challenges like poor cellular uptake and off-target effects hinder widespread application.

Purpose of the Study:

  • To present strategies for enhancing immunotoxin (IT) efficacy.
  • To address limitations in cellular uptake, cytotoxicity, and targeting specificity of existing ITs.

Main Methods:

  • Incorporating functional peptide sequences into recombinant immunotoxins.
  • Modifying ITs to improve target binding, pharmacokinetics, tumor penetration, cellular uptake, and cytotoxic efficiency.

Main Results:

  • Peptide incorporation strategies aim to enhance multiple aspects of IT function.
  • These modifications are designed to overcome key limitations of current immunotoxin therapies.

Conclusions:

  • Strategic peptide incorporation offers a promising approach to improve immunotoxin efficacy.
  • Enhanced immunotoxins hold potential for more effective cancer treatment by overcoming delivery and activity barriers.